Bristol Myers Squibb to Participate in the Guggenheim Healthcare Talks 2023 Oncology ConferenceBusiness Wire • 02/03/23
Bristol-Myers (BMY) Q4 Earnings Top, Revlimid Generic Impact SalesZacks Investment Research • 02/02/23
Bristol Myers Squibb (BMY) Q4 Earnings and Revenues Surpass EstimatesZacks Investment Research • 02/02/23
Bristol Myers Jumps On Fourth-Quarter Beat Strong Earnings OutlookInvestors Business Daily • 02/02/23
Bristol Myers Stock Rises as Revenue Falls on Lower Revlimid Sales but Profit Tops EstimatesBarrons • 02/02/23
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2022Business Wire • 02/02/23
Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl® (luspatercept) for Adult Patients with Anemia-Associated, Non-Transfusion-Dependent (NTD) Beta ThalassemiaBusiness Wire • 01/27/23
Bristol Myers Squibb Announces Positive CHMP Opinion for Once-Daily Sotyktu (deucravacitinib) as a Treatment for Adults With Moderate-to-Severe Plaque PsoriasisBusiness Wire • 01/27/23
Earnings Preview: Bristol Myers Squibb (BMY) Q4 Earnings Expected to DeclineZacks Investment Research • 01/26/23
Bristol Myers Squibb Announces TRANSCEND CLL 004 Trial of Breyanzi® (lisocabtagene maraleucel) Met Primary Endpoint of Complete Response Rate in Patients with Relapsed or Refractory Chronic Lymphocytic LeukemiaBusiness Wire • 01/26/23
The Robert A. Winn Diversity in Clinical Trials Award Program Established by the Bristol Myers Squibb Foundation to Expand with Amgen's Commitment of $8 MillionBusiness Wire • 01/19/23
Bristol Myers Squibb Wins Another Approval for Its Multimillion-Dollar Cancer DrugThe Motley Fool • 01/17/23